GlassScriptPhysician profile
Chet Monder
NPI 1427015346
$4,851.30
in general payments reported to CMS, 2019-2025
38 companies · $1,173 in 2025
The $1,173 reported for 2025 was more than what 89% of providers received nationally.
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $537 · 2020: $159 · 2021: $246 · 2022: $423 · 2023: $1,031 · 2024: $1,282 · 2025: $1,173.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,486.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,485.87 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $758.90 | 2019-2025 | Jardiance, Mounjaro, Zepbound |
| Abbott Laboratories | $468.90 | 2022-2025 | Freestyle Libre 3, Freestyle Libre 2, Proclaim |
| Sanofi-Aventis U.S. LLC | $417.59 | 2022-2025 | |
| Amgen INC. | $364.74 | 2019-2025 | Evenity, Prolia, Tepezza |
| Radius Health, INC. | $268.02 | 2022-2025 | Tymlos |
| Boehringer Ingelheim Pharmaceuticals, INC. | $217.78 | 2021-2025 | Jardiance, Synjardy, Tradjenta |
| Novo Nordisk INC | $211.14 | 2020-2025 | Ozempic, Rybelsus, Wegovy |
| Abbvie INC. | $206.59 | 2022-2025 | |
| Insulet Corporation | $174.30 | 2021-2022 | |
| Embecta Corp. | $149.96 | 2023-2024 | Bd Nano 2nd Gen Pen Needle |
| Astrazeneca Pharmaceuticals LP | $136.03 | 2019-2021 | |
| Xeris Pharmaceuticals, INC. | $135.92 | 2021-2024 | Recorlev, Gvoke Hypopen |
| Bayer Healthcare Pharmaceuticals INC. | $135.54 | 2023-2025 | |
| Tesaro, INC. | $124.99 | 2019 | |
| Amneal Pharmaceuticals LLC | $111.33 | 2021-2025 | Unithroid |
Show all 38 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Chet Monder listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.